Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) (“Supernus”) announces that it has successfully completed its previously announced acquisition of Sage Therapeutics, Inc. (Nasdaq: SAGE) (“Sage”). “Sage is an ideal fit in our corporate development strategy, adding a significant fourth growth product to our portfolio and further diversifying our sources of future revenue,” said Jack Khattar, President and CEO of Supernus Pharmaceuticals. “With our proven track record of strong commercial execution along with the expected cost synergies, the acquisition is expected to be accretive in 2026.”
Read the full article: Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics //
Source: https://www.globenewswire.com/news-release/2025/07/31/3125022/19871/en/Supernus-Pharmaceuticals-Completes-Acquisition-of-Sage-Therapeutics.html